Clinical Trial Update: Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nephron-sparing treatment with tislelizumab plus nab-paclitaxel for renal pelvis urothelial carcinoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Pelvis Urothelial Carcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Renal Pelvic Carcinoma, Tislelizumab | Phase 2 | Status: RECRUITING